A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib

Trial Profile

A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Vismodegib (Primary) ; Fluconazole; Itraconazole; Rabeprazole
  • Indications Basal cell cancer; Basal cell nevus syndrome; Breast cancer; Chondrosarcoma; Gastric cancer; Glioblastoma; Medulloblastoma; Pancreatic cancer; Prostate cancer; Sarcoma; Small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Feb 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 30 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top